Beyond Substances: Can GLP-1 Drugs Help With Gambling, Shopping, and Compulsive Behaviors?

The Anecdotes Are Everywhere

Scroll through Reddit communities or online forums for GLP-1 users and you'll find a pattern that goes beyond food and alcohol. People report that after starting semaglutide or tirzepatide, they stopped compulsive online shopping. They lost interest in gambling apps. They stopped doomscrolling. The pull toward impulsive, reward-seeking behaviors just… faded.

These reports have generated significant media attention and scientific curiosity. Researchers have started referring to GLP-1 agonists as "anti-consumption agents" — medications that dampen the drive toward overconsumption across multiple domains, whether that consumption involves food, substances, or behaviors.

But anecdotes are not evidence. So where does the science actually stand?

The Evidence Spectrum

Why the Theory Works

The scientific basis for GLP-1 effects on behavioral addictions is the same "incentive salience" framework that explains effects on substance addictions. The neuroscience model, supported by researchers including Dr. Nora Volkow at NIDA, proposes that obesity, substance use disorders, and behavioral addictions share a common mechanism: the brain assigns excessive motivational importance to certain rewards, driving compulsive pursuit despite negative consequences.

GLP-1 receptor agonists appear to modulate this shared machinery by dampening dopamine signaling in the nucleus accumbens — the brain region where the "wanting" of rewards is generated. If this mechanism truly operates at the level of general reward salience rather than substance-specific pathways, it should theoretically affect behavioral rewards (gambling wins, shopping dopamine hits) the same way it affects substance rewards (alcohol, nicotine).

This isn't just speculation — it's grounded in established neuroscience. Gambling disorder is already classified as a behavioral addiction in the DSM-5, and neuroimaging studies show that pathological gamblers exhibit the same patterns of dopamine dysregulation in reward circuits as people with substance use disorders.

Why We Should Be Cautious

The gap between theory and clinical evidence is enormous. There are several reasons to pump the brakes on excitement about GLP-1s for behavioral addictions.

First, the anecdotal reports suffer from massive selection and reporting bias. People who notice a change in their behavior are far more likely to post about it than people who notice nothing. We have no idea what percentage of GLP-1 users experience reduced compulsive behaviors versus those who don't.

Second, behavioral addictions are highly susceptible to placebo and expectancy effects. If you've read headlines about GLP-1 drugs reducing cravings, you may be primed to attribute any change in your behavior to the medication — even if it would have happened anyway.

Third, the substance addiction data — while promising — comes from large observational studies and is only beginning to be validated in controlled trials. Behavioral addiction research is years behind even that early stage.

Fourth, there's a meaningful question about whether modulating general reward sensitivity is actually desirable beyond specific clinical disorders. If GLP-1 drugs reduce the pleasure derived from shopping, socializing, hobbies, and creative pursuits alongside pathological behaviors, the net effect on quality of life becomes more complicated.

What Needs to Happen Next

For behavioral addictions, the path forward requires the same rigorous research pipeline that substance addictions are now going through: systematic documentation of prevalence (how many GLP-1 users actually report changes in gambling or shopping behavior?), observational studies using medical records or insurance data (is GLP-1 use associated with fewer gambling-related financial events?), and eventually randomized controlled trials in people diagnosed with gambling disorder or compulsive buying disorder.

None of this work has been published yet. Until it has, the honest answer to the question in this article's title is: we don't know, but the biology makes it plausible.